Prevalence and Economic Burden of Obesity-related Comorbidities in the Gulf Region: A Retrospective, Observational Study

NCT06288399 | Completed

• 2 other identifiers: DAS-7688U1111-1292-7248
• Study Type: observational
• Target: 1,316
• Locations: 3 countries
• Sites: 7

Brief Summary

The aim of this study is to assess the annual prevalence of ORCs among adult people with obesity in the real-world clinical setting across the Gulf region. In addition, the study will describe the annual HCRU and associated costs of obesity and ORCs, describe the demographics and clinical characteristics of adult people with obesity, as well as estimate the annual incidence and point prevalence of the ORCs among adult people with obesity.

Conditions

Obesity

Outcome Measures

Primary Outcomes (1)

• Proportion of Obesity Related Comorbidities (ORC, existing/newly diagnosed) among adult people with obesity (BMI above or equal to 30 kg/m2) over a period of 12 months across the Gulf region in primary and secondary hospitals as well as obesity clinics

  Percentage (and 95% CI) ORC: Dyslipidaemia, Hypertensive diseases, Type 2 diabetes mellitus, Non-alcoholic fatty liver disease, Coronary artery disease

  12-month observation period from the index date (Day 1) to Month 12 after the index date (+12 months)

Study Arms (1)

Obesity Group

Adults with diagnosis of obesity and obesity-related comorbidities

Other: No treatment given

Interventions

No treatment given OTHER

No treatment given

Obesity Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with diagnosis of obesity and obesity-related comorbidities

You may qualify if:

• Local national (male or female) of Arab ethnicity, age above or equal to 18 years at index date
• Primary or secondary diagnosis of obesity (BMI above or equal to 30 kg/m2) at index date
• Minimum of 1 visit with BMI recorded between months 1 and 6 following index date, and minimum of 1 visit with BMI recorded between months 7 and 12 following index date.
• There should be a minimum time gap of 3 months between the BMI records and the BMI must be above or equal 30 kg/m2 at each visit. If there are multiple visits during the 12-month observation period, then a mean BMI above or equal 30 kg/m2 must be maintained during the observation period.

You may not qualify if:

• Previous participation in this study. Participation is defined as having collected data of the participants in this study already.
• Participation in an interventional trial during the 12-month observation period
• Conditions associated with unintentional weight change
• Participants who underwent bariatric surgery within 18 months prior to the index date
• Participants with non-ambulatory disability diagnosis

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (7)

Farwaniya Hospital

Farwaniya, 85000, Kuwait

Location

Al-Adan Hospital

Hadiya, 52700, Kuwait

Location

Al-Amiri Hospital

Kuwait City, 13001, Kuwait

Location

National Diabetes and Endocrine Center

Muscat, 113, Oman

Location

Samail Polyclinic

Samail, 620, Oman

Location

Hamad General Hospital

Doha, 122104, Qatar

Location

PHCC

Doha, 122104, Qatar

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 23, 2024
• First Posted: March 1, 2024
• Study Start: December 21, 2023
• Primary Completion: September 30, 2024
• Study Completion: September 30, 2024
• Last Updated: October 15, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will share

Locations

OM (2); KU (3); QA (2)